Novo Nordisk INC. v. ScinoPharm Taiwan LTD.

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Novo Nordisk Inc. (Delaware) and Novo Nordisk A/S (Denmark)
  • Defendant: ScinoPharm Taiwan Ltd. (Taiwan)
  • Plaintiff's Counsel: Saul Ewing LLP
• Case Identification: 1:23-cv-20935, D.N.J., 10/05/2023
• Venue Allegations: Plaintiff alleges venue is proper because Defendant, a foreign corporation, conducts business and has systematic contacts with New Jersey, and has previously litigated in the district, thereby subjecting it to personal jurisdiction.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiff's Victoza® (liraglutide) product constitutes an act of infringement of two U.S. patents covering the drug's formulation and its injection device.
• Technical Context: The dispute involves pharmaceutical formulations for injectable peptide-based drugs used in diabetes management and the mechanical design of pen-like devices for their self-administration.
• Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendant's submission of ANDA No. 217612 and a subsequent Notice Letter, dated August 22, 2023, containing a Paragraph IV certification that the patents-in-suit are invalid, unenforceable, or will not be infringed. The complaint notes other pending litigation involving the same plaintiffs and some of the same patents against different generic drug manufacturers.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,114,833 - "Propylene Glycol-Containing Peptide Formulations Which Are Optimal for Production and For Use in Injection Devices"

The Invention Explained

• Problem Addressed: The patent addresses problems arising from the use of mannitol, a common isotonicity agent in injectable peptide formulations '833 Patent, col. 1:31-36 Mannitol can crystallize during production, leading to deposits on filling equipment, and can also cause clogging of the fine-gauge needles used in injection devices '833 Patent, col. 1:36-45
• The Patented Solution: The invention replaces mannitol with propylene glycol as the isotonicity agent in a specific pH range '833 Patent, abstract This substitution is described as reducing deposits on production equipment and minimizing the clogging of injection devices, thereby improving manufacturing efficiency and the reliability of the final product for patient use '833 Patent, col. 2:4-13 '833 Patent, col. 1:53-57
• Technical Importance: The solution provides a more stable and manufacturable formulation for widely used peptide drugs, which is critical for both mass production and patient safety in self-administered therapies.

Key Claims at a Glance

• The complaint asserts infringement of claims 1-31 Compl. ¶22 Independent claims 1, 16, 23, 26, and 29 are asserted.
• Independent Claim 1 (Composition Claim):
  • A pharmaceutical formulation comprising at least one GLP-1 agonist,
  • a disodium phosphate dihydrate buffer and
  • propylene glycol,
  • wherein said propylene glycol is present in a final concentration of from about 1 mg/ml to about 100 mg/ml,
  • and wherein said formulation has a pH of from about 7.0 to about 10.0.

U.S. Patent No. 9,265,893 - "Injection Button"

The Invention Explained

• Problem Addressed: In pen-style injection devices where setting a dose involves rotation, the push button used to inject the dose often rotates relative to a driving mechanism during actuation '893 Patent, col. 1:16-20 This relative rotation creates friction, which increases the force a user must apply, potentially making the injection difficult '893 Patent, col. 1:28-34
• The Patented Solution: The patent discloses a push button connection that minimizes this operational friction by using a "pivot bearing" between the non-rotating push button and the rotating internal driving part '893 Patent, abstract This design localizes the contact forces to a small surface area, thereby reducing the friction and the force required by the user to administer a dose '893 Patent, col. 1:50-57 Figure 1 illustrates the push button (10), the driving part (20), and the pivot bearing (18, 22) at their interface '893 Patent, Fig. 1
• Technical Importance: The invention enhances the usability of self-injection pens, a key factor for patient compliance and comfort, particularly for those who require frequent injections and may have diminished manual strength.

Key Claims at a Glance

• The complaint asserts infringement of claims 1-6 Compl. ¶28 Claim 1 is the sole independent claim.
• Independent Claim 1 (Apparatus Claim):
  • A push button connection for an injection device comprising:
  • a push button mountable on a driving part being rotatable relatively to the push button,
  • which push button further comprises a bore with a bottom surface,
  • which bore surrounds a protrusion on the driving part which protrusion has a top surface,
  • wherein a pivot bearing is formed between the bottom surface and the top surface,
  • wherein when a user presses on the push button the force is directed toward the driving part,
  • and wherein the driving part rotates relative to the push button.

III. The Accused Instrumentality

Product Identification

• Defendant's generic liraglutide injection solution, 18 mg/3 ml (6 mg/ml), for which it seeks FDA approval via ANDA No. 217612 Compl. ¶10

Functionality and Market Context

• The accused product is a generic version of Plaintiff's Victoza® product, a GLP-1 receptor agonist used for the treatment of type 2 diabetes Compl. ¶1 Compl. ¶17
• The complaint alleges that the Defendant's ANDA relies on the Victoza® New Drug Application and contains data to demonstrate bioequivalence between the accused product and Victoza® Compl. ¶18
• The complaint does not provide specific details on the excipients used in the accused formulation or the mechanical design of the injection device that will be used to administer it.

IV. Analysis of Infringement Allegations

The complaint pleads infringement in general terms, as is common in actions filed under 35 U.S.C. § 271(e)(2) shortly after receipt of a Paragraph IV notice letter. It does not include a detailed claim chart or specific mapping of accused product features to claim elements. The infringement theory is based on the allegation that the product described in the Defendant's ANDA, if commercially manufactured and sold, would meet all the limitations of the asserted claims.

No probative visual evidence provided in complaint.

'833 Patent Infringement Allegations

• The complaint alleges that the manufacture, use, or sale of the accused product would infringe claims 1-31 of the '833 Patent Compl. ¶22 This suggests that the formulation detailed in the ANDA contains liraglutide (a GLP-1 agonist) and propylene glycol in a concentration and at a pH that falls within the scope of the asserted claims, and further includes the specifically recited buffer.

'893 Patent Infringement Allegations

• The complaint alleges that the manufacture, use, or sale of the accused product would infringe claims 1-6 of the '893 Patent Compl. ¶28 This suggests that the injection device intended for use with the generic drug, as specified in the ANDA, incorporates a push button connection featuring the claimed "pivot bearing" and relative rotation between the button and a driving part.

Identified Points of Contention

• Scope Questions: A central question for the '893 Patent will be whether the mechanism in the Defendant's un-marketed injection device contains a structure that meets the definition of a "pivot bearing," a term whose scope will likely be a focus of claim construction.
• Technical Questions: For the '833 Patent, the infringement analysis will likely turn on the precise chemical composition of the accused formulation. A key question is whether the Defendant's product uses the exact "disodium phosphate dihydrate buffer" recited in independent claim 1, or a different buffering agent. For the '893 Patent, a factual question will be whether the Defendant's injection device actually exhibits relative rotation between the push button and an internal driving part during simulated use.

V. Key Claim Terms for Construction

U.S. Patent No. 8,114,833

• The Term: "a disodium phosphate dihydrate buffer" (from claim 1)
• Context and Importance: This term recites a specific chemical compound. The infringement analysis for claim 1 will depend critically on whether the Defendant's formulation contains this exact buffer. Its construction will determine whether other phosphate-based buffers, or the anhydrous form, could fall within the claim's scope, either literally or under the doctrine of equivalents.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent's overall focus is on replacing mannitol with propylene glycol to solve clogging issues, suggesting the specific buffer may not be the central point of novelty '833 Patent, col. 1:46-51
  • Evidence for a Narrower Interpretation: The claim language is highly specific, naming not only the salt but also its hydration state ("dihydrate"). The patent's examples consistently use "Disodium hydrogen phosphate, dihydrate," reinforcing that the inventors may have intended to claim this specific form '833 Patent, col. 19:11-12

U.S. Patent No. 9,265,893

• The Term: "pivot bearing" (from claim 1)
• Context and Importance: This term defines the core structural element intended to reduce friction. The outcome of the infringement analysis for the '893 patent will likely hinge on the court's construction of this term and whether the interface in the accused device meets that definition.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification describes the function of the pivot bearing as minimizing the surface area of interaction and the radius of friction, which could support a functional interpretation not limited to a single structure '893 Patent, col. 1:52-57
  • Evidence for a Narrower Interpretation: The detailed description and figures disclose a specific embodiment where the pivot bearing is formed by a "raised pointer" on the push button's bore surface pressing against the top surface of the driving part's protrusion '893 Patent, col. 3:63-65 '893 Patent, col. 4:15-18 A defendant may argue that this embodiment limits the term to a point-contact or convex-on-flat surface interface.

VI. Other Allegations

Willful Infringement

• The complaint alleges that the Defendant was aware of the '833 and '893 patents at the time it submitted its ANDA Compl. ¶25 Compl. ¶31 This awareness, likely based on the patents' listing in the FDA's Orange Book Compl. ¶16, forms the basis for Plaintiff's request for a finding of an exceptional case and an award of attorneys' fees.

VII. Analyst's Conclusion: Key Questions for the Case

The resolution of this case will likely depend on the answers to a few central questions that blend claim construction with factual findings from discovery into the specifics of the Defendant's ANDA filing.

• A core issue will be one of compositional identity: Does the formulation described in ScinoPharm's ANDA contain the precise "disodium phosphate dihydrate buffer" required by claim 1 of the '833 Patent, or does it use an alternative that will require an analysis under the doctrine of equivalents?
• A second key issue will be one of structural correspondence: Does the injection device specified in the ANDA for delivering the generic drug employ a mechanical interface between its push button and driving part that constitutes a "pivot bearing" as that term will be construed by the court, or does it manage rotational forces through a non-infringing design?